PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

• INCLUSION CRITERIA:

Inclusion Criteria- All Cohorts

• Age >= 18 years.

• Negative serum or urine pregnancy test at screening for individuals of childbearingpotential (IOCBP).

NOTE: IOCBP is defined as any individual who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal. IOCBP must have a negative pregnancy test (HCG blood or urine) during screening.

• All participants (regardless of childbearing potential) must agree to use highlyeffective contraception prior to study entry, for the duration of studyparticipation, and for 3 months after completion of study treatment for those ableto father a child or 6 months after completion of study treatment for those ofchild-bearing potential (i.e., IOCBP). Highly effective birth control (failure rateof less than 1%), e.g., intrauterine device (IUD), intrauterine hormone-releasingsystem (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence.Note: The use of condoms by participants who are able to get other individualspregnant is required unless the partner of childbearing potential is permanentlysterile.

• Nursing (including breastfeeding) participants must agree to discontinue nursing.

• Arterial anatomy on CT angiogram or CT chest, abdomen and pelvis multiphase (i.e.,CT C/A/P multiphase) amenable to placement of the HAIP.

• Participant must sign the informed consent form to participate in this study.

• HIV-positive participants may be considered for this study only if they have anundetectable viral load.

• Participants must agree to co-enroll on the Surgical Oncology Program s tissuecollection protocol 13C0176, Tumor, Normal Tissue and Specimens from PatientsUndergoing Evaluation or Surgical Resection of Solid Tumors .

• Participant s liver metastases must not be amenable to resection/ablation to NoEvidence of Disease (NED) in one stage.

• Participant must be able to tolerate systemic chemotherapy at initiation of studytreatment as outlined below (mCRC: FOLFOX or FOLFIRI; ICC: GemOx or FOLFOX; ACC:GemOx).

Inclusion Criteria-Metastatic Colorectal Carcinoma

• Participants must have histologically or cytologically confirmed diagnosis ofcolorectal adenocarcinoma metastatic to the liver (Cohort 1).

• Participants must have measurable liver metastatic disease.

• Participants must have received 1st line systemic chemotherapy.

• ECOG performance status <= 1.

• Participants must have adequate organ and marrow function as defined below:

• leukocytes > 3,000/mcL

• absolute neutrophil count > 1,500/mcL

• platelets > 90,000/mcL

• hemoglobin > 8 g/dL

• total bilirubin < 1.5 X institutional upper limit of normal

• AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal

• creatinine within normal institutional limits OR eGFR within normal aspredicted by the CKD-EPI equation > 60 mL/min/1.73 m2.

Inclusion Criteria-Intrahepatic Cholangiocarcinoma

• Participants must have histologically or cytologically confirmed diagnosis ofintrahepatic cholangiocarcinoma confined to the liver (Cohort 2). Archival tumorsample may be used but if archival tissue is not available or is not adequate,tissue biopsy will be required.

• Clinical or radiographic evidence of metastatic disease to regional (porta hepatis)lymph nodes will be allowed, provided it is amenable to resection.

• Participants must have radiographically measurable disease.

• Disease must be considered unresectable at the time of preoperative evaluation.

• Participants must have received 1st line systemic chemotherapy.

• ECOG performance status <=1.

• Participants must have adequate organ and marrow function as defined below:

• leukocytes >= 2,000/ mm^3

• absolute neutrophil count > 1,500/mcL

• platelets >= 75,000/ mm^3

• hemoglobin > 8 g/dL

• total bilirubin < 1.5 mg/dl

• creatinine <= 1.5 mg/dl

Inclusion Criteria-Adrenocortical Carcinoma

• Participants must have histologically or cytologically confirmed diagnosis ofadrenocortical carcinoma (ACC), also referred to as adrenocortical cancer .

• Participants must have received at least one line of systemic chemotherapy.

• Participants must have measurable liver metastatic disease.

• ECOG performance status <= 1.

• Participants must have adequate organ and marrow function as defined below:

• leukocytes > 3,000/mcL

• absolute neutrophil count > 1,500/mcL

• platelets > 90,000/mcL

• hemoglobin > 8 g/dL

• total bilirubin < 1.5 X institutional upper limit of normal

• AST(SGOT)/ALT(SGPT) < 3 X institutional upper limit of normal

• creatinine < 2 X institutional upper limit of normal

EXCLUSION CRITERIA:

Exclusion Criteria- All Cohorts

Participants who are receiving any other investigational agents.

• Participants who have previously received rIL-12.

• Participants with active autoimmune diseases, that might deteriorate when receivingan immunostimulatory agent with the exceptions:

• diabetes type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid diseasenot requiring immunosuppressive treatment are eligible;

• participants requiring hormone replacement with corticosteroids are eligible ifthe steroids are administered only for the purpose of hormonal replacement andat doses <= 10 mg of prednisone or equivalent per day;

• administration of steroids for other conditions through a route known to resultin a minimal systemic exposure (topical, intranasal, intro-ocular, orinhalation) is eligible.

• History of organ transplant, except for transplants that do not requireimmunosuppression.

• History of or active inflammatory bowel disease (e.g., Crohn s disease, ulcerativecolitis).

• Known hypersensitivity or allergic reactions attributed to any compounds of similarchemical or biologic composition to the study medication, such as recombinant IL-12or other monoclonal antibodies and history of allergic reactions attributed tocompounds of similar chemical composition to FUDR or heparin.

• Clinically significant (i.e., active) cardiovascular disease: cerebral vascularaccident/stroke < 6 months prior to enrollment, myocardial infarction < 6 monthsprior to enrollment, unstable angina, congestive heart failure (>= NYHA III) orserious cardiac arrhythmia requiring medication.

• All conditions associated with significant necrosis of nontumor-bearing tissues.

• Esophageal or gastroduodenal ulcers < 6 months prior to treatment.

• Active ischemic bowel disease.

• Psychiatric illness/social situations that would limit compliance with studyrequirements.

• Active concurrent malignancies within the last five years other than colorectalprimary except basal cell skin carcinoma and thyroid carcinoma.

• Prior radiation to liver.

• Participants with active Hepatitis B or C infection.

• Significant acute or chronic infections (i.e., tuberculosis) history of exposure orhistory of positive tuberculosis test; plus, presence of clinical symptoms, physicalor radiographic findings).

• Any condition, including the presence of laboratory abnormalities and/orinsufficient normal liver parenchyma, which places the participant at unacceptablerisk if they were to participate in the study or confounds the ability to interpretdata from the study.

Exclusion Criteria-Metastatic Colorectal Carcinoma

-Participants with incontrovertible radiographic evidence of disease outside of the colon/rectum (primary) and liver given unlikelihood of benefit from liver-directed therapy.

Note: Lung lesions seen on CT do not always represent metastases. They are very hard to qualify, therefore exception to this exclusion is participants with fewer than five lung lesions greater than 1 cm that have not increased in size by more than 10% over a 4-month period of time and are amenable to resection should subsequent problematic growth occur. Lesions less than 1 cm are indeterminant as far as etiology is concerned and will be ignored. Participants with liver metastases and oligometastatic lung lesions (we define oligometastatic as less than 5 amenable to thoracoscopic removal) are still likely to benefit from liver directed therapy.

• Participants who have undergone extra-hepatic metastasectomy and have a documenteddisease-free interval less than or equal to 4 months.

• Participants with a history of MSI-high results who need to be treated withcheck-point inhibitors.

• Prior treatment with FUDR.

Exclusion Criteria-Intrahepatic Cholangiocarcinoma

-Presence of distant metastatic disease. Clinical or radiographic evidence of metastatic disease to regional lymph nodes will be allowed, provided it is amenable to resection.

Note: Lung lesions seen on CT do not always represent metastases. They are very hard to qualify, therefore exception to this exclusion is participants with fewer than five lung lesions greater than 1 cm that have not increased in size by more than 10% over a 4-month period of time and are amenable to resection should subsequent problematic growth occur. Lesions less than 1 cm are indeterminate as far as etiology is concerned and will be ignored. Participants with liver metastases and oligometastatic lung lesions (we define oligometastatic as less than 5 amenable to thoracoscopic removal) are still likely to benefit from liver directed therapy.

• Prior treatment with FUDR.

• Diagnosis of sclerosing cholangitis.

• Clinical evidence or portal hypertension (ascites, gastroesophageal varices, orportal vein thrombosis).

Exclusion Criteria-Adrenocortical Carcinoma

• Participants with incontrovertible radiographic evidence of additional abdominaldisease outside of the liver (including the primary tumor) that is not amenable tocomplete surgical extirpation at the time of pump placement.

• Clinical evidence or portal hypertension (ascites, gastroesophageal varices, orportal vein thrombosis).

• Diagnosis of sclerosing cholangitis.

• Participants with pulmonary metastases that have progressed by RECIST criteria inthe preceding 3 months prior to study enrollment.

• Participants with known mismatch repair mutation who have not been treated with acheckpoint inhibitor. Acceptable methods of MSI testing for history of MSI resultsinclude immunohistochemistry (IHC) and next generation sequencing (NGS) of tumormaterial.